They can include: cold sweat, cool pale skin, headache, fast heartbeat, feeling sick (nausea) or very hungry, changes in vision, feeling sleepy or weak, feeling nervous, anxious or confused, difficulty concentrating or shaking
Researchers continue investigating how GLP-1 signaling contributes to metabolic regulation and nutrient processing
The DAPA-HF, EMPEROR-REDUCED, EMPEROR-Preserved, DELIVER and other trials mentioned above consistently demonstrate the efficacy of SGLT-2i in patients with HF, regardless of LVEF or the presence of diabetes
A few factors can shape outcomes: Starting weight and body composition Consistency with injections and follow-up The specific medication and dose tolerated Nutrition quality and protein intake Physical activity, especially strength work Sleep, stress, and hormonal balance Other medical conditions or medications These details help explain why GLP-1 weight loss results are best discussed in a medical setting instead of being judged against social media updates or celebrity headlines
Wegovy has demonstrated sustained benefits, with approximately 77% of patients on Wegovy maintaining at least a 5% weight loss at the two-year mark
This hormone influences appetite and caloric intake mainly through its action on gastric emptying and appetite suppression